GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that she will step down as Chief Executive Officer and as a member of the Board when Mr. Cunningham joins GeneDx. Ms. Stueland will remain with GeneDx in an advisory capacity through January 31, 2027 to support a smooth transition.
Mr. Cunningham joins GeneDx from Quanterix Corporation, where he most recently served as President and Chief Executive Officer. He brings more than 35 years of experience building and leading commercial organizations across diagnostics, genomics, medical technology and pharmaceuticals, including senior roles at Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics and Pfizer. Mark Gardner will continue to serve as President, reporting to Mr. Cunningham.
“Everett is one of the most accomplished commercial leaders in our industry, and he is the right person to lead GeneDx into its next phase of growth,” said Keith Meister, Chairman of the GeneDx Board of Directors. “For more than three decades, Everett has built and led high-performing commercial organizations at some of the most important companies in healthcare and is uniquely positioned to move innovative diagnostics from early adoption to standard of care as we embrace the opportunity to bring exome and genome sequencing to more clinicians and families.”
Mr. Meister continued, “On behalf of the Board, I want to thank Katherine for her transformational leadership over the past five years. She led GeneDx through its combination with Sema4, delivered significant revenue growth, and helped establish GeneDx as the leader in rare disease diagnosis. We are grateful for everything she has accomplished and the lasting impact of her leadership.”
“GeneDx has built a remarkable foundation, with unmatched clinical expertise, the world’s largest rare disease genomic dataset and a team that is deeply committed to the families it serves,” said Mr. Cunningham. “I have spent my career helping bring innovative diagnostics to clinicians and patients at scale, and I believe GeneDx has a tremendous opportunity to make exome and genome sequencing the first-line standard of care. I’m excited to work with GeneDx President Mark Gardner, the leadership team and the Board to accelerate adoption, execute with discipline and deliver for patients and shareholders alike.”
“Five and a half years ago, I joined GeneDx as CEO to lead its transformation into an independent company, grow the business, and achieve profitability. Together, we’ve delivered on all these commitments. Most of all, I’m proud of what all this work adds up to: more families getting an accurate diagnosis sooner. Part of this journey has been building an exceptional team to lead our next phase of growth, and now is a natural time for me to pass the baton. I’m delighted to welcome Everett and look forward to seeing GeneDx go from strength to strength,” said Ms. Stueland.
GeneDx also reaffirmed its full year 2026 financial guidance, as provided on November 9, 2026, in connection with the release of its third quarter 2026 financial results.
Read more here.